Evidence map›Paper›PMID 36625851›Full record

ReviewCancer research2023

Case Studies for Overcoming Challenges in Using Big Data in Cancer.

Shawn M Sweeney, Hisham K Hamadeh, Natalie Abrams, Stacey J Adam, Sara Brenner, Dana E Connors, Gerard J Davis, Louis D Fiore, Susan H Gawel, Robert L Grossman and 20 more

Open access · hybridAbstract readReview
In one paragraph

Review in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 19 institutions in 4 countries.

Shawn M SweeneyAmerican Association for Cancer Research, Philadelphia, Pennsylvania.ORCID 0000-0002-4269-6566
Hisham K HamadehGenmab, Princeton, New Jersey.ORCID 0000-0002-6800-2120
Natalie AbramsDivision of Cancer Prevention, Early Detection Research Network, National Cancer Institute, Rockville, Maryland.ORCID 0000-0001-9698-2819
Stacey J AdamFoundation for the National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-4590-5175
Sara BrennerOffice of In Vitro Diagnostics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland.ORCID 0000-0002-0999-7674
Dana E ConnorsFoundation for the National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7930-6843
Gerard J DavisAbbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.ORCID 0000-0002-4149-1999
Louis D FioreBoston University School of Medicine, Boston and New England Department of Veterans Affairs, Bedford, Massachusetts.ORCID 0000-0002-2195-5186
Susan H GawelAbbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.ORCID 0000-0003-3295-7539
Robert L GrossmanCenter for Translational Data Science, The University of Chicago, Chicago, Illinois.ORCID 0000-0003-3741-5739
Sean E HanlonCenter for Strategic Scientific Initiatives, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0001-6899-6906
Karl HsuSanofi, Bridgewater, New Jersey.ORCID 0000-0003-3137-1202
Gary J KelloffDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-5656-4900
Ilan R KirschAdaptive Biotechnologies, Seattle, Washington.ORCID 0000-0001-5592-5201
Bill LouvProject Data Sphere, Morrisville, North Carolina.ORCID 0000-0002-2789-4994
Deven McGrawCiitizen Platform at Invitae, San Francisco, California.ORCID 0000-0002-8172-4400
Frank MengBoston University and Veterans Administration Boston Healthcare System, Boston, Massachusetts.ORCID 0000-0002-3065-1619
Daniel MilgramCCS Associates, San Jose, California.ORCID 0000-0001-7287-9307
Robert S MillerCancerLinQ, American Society of Clinical Oncology, Alexandria, Virginia.ORCID 0000-0003-0869-6316
Emily MorganFoundation for the National Institutes of Health, Bethesda, Maryland.ORCID 0000-0003-2031-4341
Lata MukundanCCS Associates, San Jose, California.ORCID 0000-0002-7608-3557
Thomas O'BrienPfizer, Brooklyn, New York.ORCID 0000-0002-9161-8070
Paul RobbinsPfizer, Brooklyn, New York.ORCID 0000-0003-3704-4616
Eric H RubinMerck, New York, New York.ORCID 0000-0002-8032-7913
Wendy S RubinsteinOffice of In Vitro Diagnostics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland.
Liz SalmiBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3798-7438
Teilo H SchallerProject Data Sphere, Morrisville, North Carolina.ORCID 0000-0002-5036-5820
George ShiAbbott Diagnostics Division, Abbott Laboratories, Lake Forest, Illinois.ORCID 0000-0001-5689-9359
Caroline C SigmanBoston University and Veterans Administration Boston Healthcare System, Boston, Massachusetts.ORCID 0000-0001-6623-4107
Sudhir SrivastavaCancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland.ORCID 0000-0002-7798-9772
Abbott Fund · USFoundation for the National Institutes of Health · USCCS Associates (United States) · USCenter for Devices and Radiological Health · USNational Cancer Institute · MYNational Cancer Institute · USNorth Carolina Institute of Medicine · USPfizer (United States) · USVA Boston Healthcare System · USAdaptive Biotechnologies (United States) · USAmerican Association For Cancer Research · USAmerican Society of Clinical Oncology · USBeth Israel Deaconess Medical Center · USGenmab (United States) · USInvitae (United States) · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USSanofi (United States) · USUniversity of Chicago · USVA New England Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating, and making these data readily accessible to the research community. This review presents five case studies illustrating various successful approaches to addressing such challenges. These efforts are CancerLinQ, the American Association for Cancer Research Project GENIE, Project Data Sphere, the National Cancer Institute Genomic Data Commons, and the Veterans Health Administration Clinical Data Initiative. Critical factors in the development of these systems include attention to the use of robust pipelines for data aggregation, common data models, data deidentification to enable multiple uses, integration of data collection into physician workflows, terminology standardization and attention to interoperability, extensive quality assurance and quality control activity, incorporation of multiple data types, and understanding how data resources can be best applied. By describing some of the emerging resources, we hope to inspire consideration of the secondary use of such data at the earliest possible step to ensure the proper sharing of data in order to generate insights that advance the understanding and the treatment of cancer.

Indexed as

Big DataNeoplasmsDelivery of Health CareHumansMedical OncologyUnited States

Identifiers

PMID36625851
PMCPMC10102839
OpenAlexW4315436138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.